182 related articles for article (PubMed ID: 11083647)
21. Construction of a replication-competent hepatitis B virus vector carrying secreted luciferase transgene and establishment of new hepatitis B virus replication and expression cell lines.
Ruan J; Ping CY; Sun S; Cheng X; Han PY; Zhang YG; Sun DX
World J Gastroenterol; 2019 Oct; 25(39):5961-5972. PubMed ID: 31660033
[TBL] [Abstract][Full Text] [Related]
22. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells.
Korba BE; Boyd MR
Antimicrob Agents Chemother; 1996 May; 40(5):1282-4. PubMed ID: 8723485
[TBL] [Abstract][Full Text] [Related]
23. Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
Geipel A; Seiz PL; Niekamp H; Neumann-Fraune M; Zhang K; Kaiser R; Protzer U; Gerlich WH; Glebe D;
Antivir Ther; 2015; 20(8):779-87. PubMed ID: 25560463
[TBL] [Abstract][Full Text] [Related]
24. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture.
Ying C; De Clercq E; Neyts J
J Viral Hepat; 2000 Jan; 7(1):79-83. PubMed ID: 10718947
[TBL] [Abstract][Full Text] [Related]
25. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
26. Robustaflavone, a potential non-nucleoside anti-hepatitis B agent.
Zembower DE; Lin YM; Flavin MT; Chen FC; Korba BE
Antiviral Res; 1998 Aug; 39(2):81-8. PubMed ID: 9806485
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
Melegari M; Scaglioni PP; Wands JR
Hepatology; 1998 Feb; 27(2):628-33. PubMed ID: 9462667
[TBL] [Abstract][Full Text] [Related]
28. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
Kumar R; Semaine W; Johar M; Tyrrell DL; Agrawal B
J Med Chem; 2006 Jun; 49(12):3693-700. PubMed ID: 16759112
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
Zoulim F
Antivir Chem Chemother; 2001; 12 Suppl 1():131-42. PubMed ID: 11594680
[TBL] [Abstract][Full Text] [Related]
30. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.
Fu L; Cheng YC
Biochem Pharmacol; 1998 May; 55(10):1567-72. PubMed ID: 9633992
[TBL] [Abstract][Full Text] [Related]
31. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus.
Sun D; Nassal M
J Hepatol; 2006 Nov; 45(5):636-45. PubMed ID: 16935386
[TBL] [Abstract][Full Text] [Related]
32. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
Ren GL; Fang Y; Ma HH; Lei YF; Wang D; Xu MC; Wang PZ; Huang CX; Nie OH; Sun YT; Bai XF
Antivir Ther; 2007; 12(6):865-76. PubMed ID: 17926641
[TBL] [Abstract][Full Text] [Related]
33. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
34. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
Pichoud C; Seignères B; Wang Z; Trépo C; Zoulim F
Hepatology; 1999 Jan; 29(1):230-7. PubMed ID: 9862871
[TBL] [Abstract][Full Text] [Related]
35. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Billioud G; Pichoud C; Puerstinger G; Neyts J; Zoulim F
Antiviral Res; 2011 Nov; 92(2):271-6. PubMed ID: 21871497
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
37. Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates.
Zhou Y; Zhang Y; Yang X; Zhao J; Zheng L; Sun C; Jiang J; Yang Q; Wang Q; Chang J
Antivir Ther; 2012; 17(8):1593-9. PubMed ID: 22910281
[TBL] [Abstract][Full Text] [Related]
38. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
Seignères B; Pichoud C; Martin P; Furman P; Trépo C; Zoulim F
Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro.
Jung J; Kim NK; Park S; Shin HJ; Hwang SG; Kim K
BMC Complement Altern Med; 2015 Jul; 15():255. PubMed ID: 26220282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
